EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische Studie

Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia

Christie M Ballantyne, Szilard Vasas, Masoud Azizad, Peter Clifton, Robert S Rosenson, Ting Chang, Stacey Melquist, Rong Zhou, Ma'an Mushin, Nicholas J Leeper, Jennifer Hellawell, Daniel Gaudet

New England Journal of Medicine · 12.09.2024 · 391 (10) · 899-912

DOI: 10.1056/nejmoa2404143 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 12.09.2024. Verfasst von Christie M Ballantyne und 11 weiteren Autor:innen. Beteiligte Einrichtung: From the Baylor College of Medicine and the Texas Heart Institute, Houston (C.M.B.); Borbánya Praxis, Nyíregyháza, Hungary (S.V.); Valley Clinical Tr…. Hauptthemen laut MEDLINE: Apolipoprotein C-III, Hyperlipidemias, RNA, Small Interfering, Triglycerides. Die Arbeit wurde bisher 220-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: Arrowhead Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Apolipoprotein C-IIIHyperlipidemiasRNA, Small InterferingTriglyceridesRNAi TherapeuticsAdultAgedFemaleHumansMaleMiddle AgedCholesterol, LDLDose-Response Relationship, DrugDouble-Blind Method

Substanzen

APOC3 protein, humanApolipoprotein C-IIICholesterol, LDLRNA, Small InterferingTriglycerides

Autor:innen und Institutionen

  • From the Baylor College of Medicine and the Texas Heart Institute, Houston (C.M.B.); Borbánya Praxis, Nyíregyháza, Hungary (S.V.); Valley Clinical Trials, Northridge (M.A.), Arrowhead Pharmaceuticals, Pasadena (T.C., S.…

Förderung

  • Arrowhead Pharmaceuticals

Zitieren

APA

Ballantyne, C. M., Vasas, S., Azizad, M., Clifton, P., Rosenson, R. S., Chang, T., Melquist, S., Zhou, R., Mushin, M., Leeper, N. J., Hellawell, J., & Gaudet, D. (2024). Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. New England Journal of Medicine, 391(10), 899-912. https://doi.org/10.1056/nejmoa2404143

Vancouver

Ballantyne CM, Vasas S, Azizad M, Clifton P, Rosenson RS, Chang T, et al. Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia. New England Journal of Medicine. 2024;391(10):899-912. doi:10.1056/nejmoa2404143

BibTeX
@article{Ballantyne2024,
  author = {Ballantyne, Christie M and Vasas, Szilard and Azizad, Masoud and Clifton, Peter and Rosenson, Robert S and Chang, Ting and Melquist, Stacey and Zhou, Rong and Mushin, Ma'an and Leeper, Nicholas J and Hellawell, Jennifer and Gaudet, Daniel},
  title = {Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {10},
  pages = {899--912},
  doi = {10.1056/nejmoa2404143}
}
Kostenlos starten →